Swiss giant Roche’s (SWX: ROG, OTCMKTS: RHHBY) China unit has entered into a collaboration agreement with JD Healthcare, a unit of China’s e-commerce giant JD.com (NASDAQ: JD). This partnership aims to enhance the prevention and control of influenza in China through the innovative “medicine+Internet medicine” model, making Xofluza (baloxavir marboxil) more accessible to Chinese patients.
Enhancing Public Awareness
The collaboration seeks to boost public awareness and knowledge about influenza prevention and control. By utilizing JD Healthcare’s platform, the duo plans to roll out educational programs and campaigns to equip the public with essential information for preventing the flu. This initiative is expected to reach a wide audience, promoting healthier communities nationwide.
Supporting Healthcare Professionals
JD Healthcare will also provide continuous academic training for internet doctors on its platform. This training will focus on the latest advancements in influenza treatment, helping doctors improve their professional skills and deliver more precise and efficient diagnosis and treatment services. The collaboration will also facilitate continuous professional development for healthcare providers.
Multi-Party Collaboration
The partnership will bring together industry, academic, research, and medical stakeholders. By creating a dialogue platform and cooperation bridge, the collaboration will enable all parties to work together to explore integrated solutions for influenza prevention and control. This multi-faceted approach is expected to lead to more comprehensive and effective strategies for combating the flu.-Fineline Info & Tech
Leave a Reply